Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m(2) versus 40 mg/m(2) in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

OBJECTIVE: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m(2) every 4 weeks. While 40 mg/m(2) has recently been used in clinical practice, evidence supporting this use remains lacking. METHODS: This phase III randomized, non-inferiority study compared progression-free survival...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Gynecol Oncol
Hauptverfasser: Motohashi, Takashi, Yabuno, Akira, Michimae, Hiroshi, Ohishi, Tetsuro, Nonaka, Miwa, Takano, Masashi, Nishio, Shin, Fujiwara, Hiroyuki, Fujiwara, Keiichi, Kondo, Eiji, Sugiyama, Toru, Tabata, Tsutomu
Format: Artigo
Sprache:Inglês
Veröffentlicht: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2020
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7767649/
https://ncbi.nlm.nih.gov/pubmed/33185050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2021.32.e9
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge